# US 6,730,685 B1 · Formulation of substituted benzimidazoles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,685 B1
- Document ID: US6730685B1
- Status: Granted
- Kind: B1
- Application number: 09/701,714
- Filed: 2000-12-01
- Granted: 2004-05-04
- Earliest claimed: 1999-10-22
- Assignees: AstraZeneca AB
- Inventors: Mikael Brülls
- Web page: https://patentgrep.com/patent/US6730685B1

## CPC

- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to stable liquid formulations that comprise a water free or almost water free, polyethylene glycol solution of sodium or potassium salt of a H+, K+-ATPase inhibitor of Formula I or a sodium or potassium salt of one single enantiomer thereof. Alternatively, the sodium or potassium salt of the H+, K+-ATPase inhibitor may be formed in situ in the polyethylene glycol solution by adding sodium or potassium hydroxide together and the active compound. The invention is also directed to the preparation of the claimed formulation, use of the stable liquid formulations in medicine and in the treatment of gastrointestinal diseases.

## Claims

### Claim 1

A water free or almost water free, stable liquid formulation comprising polyethylene glycol and a sodium or potassium salt of a H+, K+-ATPase inhibitor, and optionally pharmaceutically acceptable excipients that are soluble in the formulation.

### Claim 2 (depends on 1)

The stable liquid formulation according to claim 1, wherein the sodium or potassium salt of the H+,K+-ATPase inhibitor is a sodium or potassium salt of a compound with the general formula I, or a sodium or potassium salt of the single enantiomer thereof
wherein
Het1 is
Het1 is
B=
wherein
N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R6-R9 optionally may be exchanged for a Ditrogen atom without any substituents;
R1, R2 and R3 are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy unsubstituted or substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;
R4 and R5 are the same or different and selected from the group consisting of hydrogen, alkyl and arylalkyl;
R6′ is selected from the group consisting of hydrogen, halogen, trifluoromethyl, alkyl and alkoxy,
R6-R9 are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, and trifluoroalkyl, or adjacent groups R6-R9 form ring structures which may be ether substituted;
R10 is hydrogen or forms an alkylene chain together with R3; and
R11 and R12 are the same or different and selected from the group consisting of hydrogen, halogen and alkyl.

### Claim 3 (depends on 2)

The stable liquid formulation according to claim 2, wherein the sodium or potassium salt of the H+,K+-ATPase inhibitor is the sodium or potassium salt of a compound with any of the following formulas, or the sodium or potassium salt of the single enantiomer thereof

### Claim 4 (depends on 1, 2, 3)

The stable liquid formulation according to any of claims 1-3, wherein the compound is a sodium salt.

### Claim 5 (depends on 1, 2, 3)

The stable liquid formulation according to any of claims 1-3, wherein the compound is a potassium salt.

### Claim 6 (depends on 4)

The stable liquid formulation according to claim 4, wherein the compound is the sodium salt of (S)-omeprazole or the sodium salt of omeprazole.

### Claim 7 (depends on 1)

The stable liquid formulation according to any of claims 1—3, wherein the polyethylene glycol is selected from polyethylene glycol 200, 300 and 400.

### Claim 8 (depends on 7)

The stable liquid formulation according to claim 7, wherein the polyethylene glycol is polyethylene glycol 400.

### Claim 9 (depends on 1)

The stable liquid formulation according to any of claims 1—3, wherein the water content of the solution is less than 6% by weight.

### Claim 10 (depends on 9)

The stable liquid formulation according to claim 9, wherein the water content is less than 3% by weight.

### Claim 11 (depends on 10)

The stable liquid formulation according to claim 10, wherein the water content is less than 2% by weight.

### Claim 12

A process for the preparation of a water free or a most water free stable liquid formulation comprising polyethylene glycol and a sodium or potassium salt of a H+,K30 -ATPase inhibitor, and optionally pharmaceutically acceptable excipients that are soluble in the formulation, wherein the sodium or potassium salt of the H+,K+-ATPase inhibitor and polyethylene glycol are mixed, and optional excipients are added, whereafter the solution optionally is purged with nitrogen to obtain a water content of a pre-set value.

### Claim 13

A process for the preparation of a water free or almost water free stable liquid formulation comprising polyethylene glycol and a sodium or potassium salt of a H+,K30 -ATPase inhibitor, and optionally pharmaceutically acceptable excipients that are soluble in the formulation, wherein the H+,K+-ATPase inhibitor, sodium or potassium hydroxide and polyethylene glycol are mixed, and optional excipients are added, whereafter the solution optionally is purged with nitrogen to obtain a water content of a pre-set value.

### Claim 14 (depends on 11, 12)

The process according to claim 11 or 12, wherein the process further comprises the step that the liquid formulation is sterile filtered.

### Claim 15 (depends on 1)

A method for treating gastrointestinal diseases wherein a therapeutically effective amount of a stable liquid formulation according to any of claims 1—3 is administered to a subject in need thereof.
